News >

FDA Approves Dasatinib for Pediatric Ph+ Chronic Phase CML

Jason Broderick
Published: Friday, Nov 10, 2017

Lia Gore, MD

Lia Gore, MD
The FDA has approved dasatinib (Sprycel) for the treatment of pediatric patients with Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia (CML) in chronic phase (CP).
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: New Directions in Advanced Cutaneous Squamous Cell Carcinoma: Emerging Evidence of ImmunotherapyAug 13, 20191.5
Advances in™ Multiple Myeloma: Changing Treatment Paradigms and the Emerging Potential of CAR T-Cell TherapyAug 30, 20191.5
Publication Bottom Border
Border Publication
x